Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Taming the dragon: genomic biomarkers to individualize the treatment of cancer.

Literature DB >> 21386834

Taming the dragon: genomic biomarkers to individualize the treatment of cancer.

Abstract

The gradual shift from cytotoxic drugs to highly selective, targeted therapeutic agents for cancer requires a parallel effort to characterize cancers at the molecular level to guide the choice of therapy for the individual patient. Here we review the genomic technologies that can be used to develop these drug response indicators, or biomarkers. We also discuss hurdles in their development and the implementation of biomarkers in clinical practice.

Entities: Disease Species

Mesh：

Substances：
Biomarkers, Tumor

Year: 2011 PMID： 21386834 DOI： 10.1038/nm.2311

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

123 in total

1. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Authors: Wendy De Roock; Derek J Jonker; Federica Di Nicolantonio; Andrea Sartore-Bianchi; Dongsheng Tu; Salvatore Siena; Simona Lamba; Sabrina Arena; Milo Frattini; Hubert Piessevaux; Eric Van Cutsem; Chris J O'Callaghan; Shirin Khambata-Ford; John R Zalcberg; John Simes; Christos S Karapetis; Alberto Bardelli; Sabine Tejpar
Journal: JAMA Date: 2010-10-27 Impact factor: 56.272

2. Next-generation sequencing of plasma/serum DNA: an emerging research and molecular diagnostic tool.

Authors: Y M Dennis Lo; Rossa W K Chiu
Journal: Clin Chem Date: 2009-02-20 Impact factor: 8.327

3. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors: Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal: Cancer Cell Date: 2005-04 Impact factor: 31.743

4. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.

Authors: Simon A Joosse; Kim I M Brandwijk; Peter Devilee; Jelle Wesseling; Frans B L Hogervorst; Senno Verhoef; Petra M Nederlof
Journal: Breast Cancer Res Treat Date: 2010-07-08 Impact factor: 4.872

5. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors: Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal: Science Date: 2010-09-08 Impact factor: 47.728

Review 6. Circulating tumour cells in cancer patients: challenges and perspectives.

Authors: Klaus Pantel; Catherine Alix-Panabières
Journal: Trends Mol Med Date: 2010-07-29 Impact factor: 11.951

Review 7. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin.

Authors: Federico A Monzon; Tracie J Koen
Journal: Arch Pathol Lab Med Date: 2010-02 Impact factor: 5.534

8. A comprehensive catalogue of somatic mutations from a human cancer genome.

Authors: Erin D Pleasance; R Keira Cheetham; Philip J Stephens; David J McBride; Sean J Humphray; Chris D Greenman; Ignacio Varela; Meng-Lay Lin; Gonzalo R Ordóñez; Graham R Bignell; Kai Ye; Julie Alipaz; Markus J Bauer; David Beare; Adam Butler; Richard J Carter; Lina Chen; Anthony J Cox; Sarah Edkins; Paula I Kokko-Gonzales; Niall A Gormley; Russell J Grocock; Christian D Haudenschild; Matthew M Hims; Terena James; Mingming Jia; Zoya Kingsbury; Catherine Leroy; John Marshall; Andrew Menzies; Laura J Mudie; Zemin Ning; Tom Royce; Ole B Schulz-Trieglaff; Anastassia Spiridou; Lucy A Stebbings; Lukasz Szajkowski; Jon Teague; David Williamson; Lynda Chin; Mark T Ross; Peter J Campbell; David R Bentley; P Andrew Futreal; Michael R Stratton
Journal: Nature Date: 2009-12-16 Impact factor: 49.962

9. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

Authors: Lao H Saal; Peter Johansson; Karolina Holm; Sofia K Gruvberger-Saal; Qing-Bai She; Matthew Maurer; Susan Koujak; Adolfo A Ferrando; Per Malmström; Lorenzo Memeo; Jorma Isola; Pär-Ola Bendahl; Neal Rosen; Hanina Hibshoosh; Markus Ringnér; Ake Borg; Ramon Parsons
Journal: Proc Natl Acad Sci U S A Date: 2007-04-23 Impact factor: 11.205

10. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

Authors: Nathan T Ihle; Robert Lemos; Peter Wipf; Adly Yacoub; Clint Mitchell; Doris Siwak; Gordon B Mills; Paul Dent; D Lynn Kirkpatrick; Garth Powis
Journal: Cancer Res Date: 2009-01-01 Impact factor: 12.701

21 in total

1. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Authors: Ariel Lopez-Chavez; Anish Thomas; Arun Rajan; Mark Raffeld; Betsy Morrow; Ronan Kelly; Corey Allan Carter; Udayan Guha; Keith Killian; Christopher C Lau; Zied Abdullaev; Liqiang Xi; Svetlana Pack; Paul S Meltzer; Christopher L Corless; Alan Sandler; Carol Beadling; Andrea Warrick; David J Liewehr; Seth M Steinberg; Arlene Berman; Austin Doyle; Eva Szabo; Yisong Wang; Giuseppe Giaccone
Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544

2. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.

Authors: Dingxie Liu; Xuan Liu; Mingzhao Xing
Journal: Cell Cycle Date: 2013-10-29 Impact factor: 4.534

3. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.

Authors: Simon M Denley; Nigel B Jamieson; Pamela McCall; Karin A Oien; Jennifer P Morton; C Ross Carter; Joanne Edwards; Colin J McKay
Journal: J Gastrointest Surg Date: 2013-02-23 Impact factor: 3.452

Taming the dragon: genomic biomarkers to individualize the treatment of cancer.

1. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

2. Next-generation sequencing of plasma/serum DNA: an emerging research and molecular diagnostic tool.

3. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

4. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.

5. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Review 6. Circulating tumour cells in cancer patients: challenges and perspectives.

Review 7. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin.

8. A comprehensive catalogue of somatic mutations from a human cancer genome.

9. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

10. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

1. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

2. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.

3. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.

4. Test set bias affects reproducibility of gene signatures.

Review 5. Multiscale integration of -omic, imaging, and clinical data in biomedical informatics.

6. Inference for multimarker adaptive enrichment trials.

Review 7. Cancer biomarkers: selecting the right drug for the right patient.

8. TGF-β: an emerging player in drug resistance.

9. Modeling factors critical for implementation of precision medicine at health systems-level: an IRT approach.

10. 2dFDR: a new approach to confounder adjustment substantially increases detection power in omics association studies.